Amongst chemokine receptors the ones most frequently expressed on stromal cells belong to the 23 atypical chemokine receptor subfamily. These receptors do not signal in the classic sense in response 24 to ligand but scavenge their ligands and degrade them and thus sculpt in vivo chemokine gradients. 25
Here we demonstrate the ability to use either intratracheal, or intravenous, Alexa-Fluor labelled 26 chemokine administration to detect stromal cell populations expressing the atypical chemokine 27 receptor ACKR2. Using this methodology we demonstrate, for the first time, expression of ACKR2 on 28 blood endothelial cells. This observation sets the lung aside from other tissues in which ACKR2 is 29 exclusively expressed on lymphatic endothelial cells. In summary therefore we described a novel 30 method for the in situ labelling of atypical chemokine receptor expressing cells appropriate for 31 subsequent flow cytometric analysis. We propose that this methodology will work in a range of species 32 and for a range of receptors and therefore will have significant versatility 33 34 35
Introduction. 36
In vivo leukocyte migration is regulated, in the main, by proteins belonging to the chemokine 37 family of chemotactic cytokines (1, 2) . This family is defined on the basis of a conserved cysteine motif 38 in the mature sequence of its members and is divided into CC, CXC, XC and CX3C subfamilies according 39 to the specific configuration of this motif. The chemokine family arose early in vertebrate evolution (3) 40 (pre-vertebrate species do not have chemokines) and the primordial chemokine was almost certainly 41 CXCL12 which plays essential roles in stem cell migration during embryogenesis (4) (5) (6) (7) (8) (9) . From this one 42 chemokine and its receptor CXCR4, through gene duplication, the family has expanded to the point at 43 which mammals have approximately 45 chemokines, and 18 signalling chemokine receptors, which 44 together orchestrate in vivo homeostatic and inflammatory leukocyte migration. Chemokine 45 regulation of cellular migration is extremely complex and, particularly in the case of inflammation(10), 46
poorly understood which has contributed to ongoing problems in therapeutically targeting 47 inflammatory chemokine receptors in immune and inflammatory diseases (11) . 48
In addition to signalling chemokine receptors which belong to the G-protein coupled receptor 49 family(12), chemokines also bind to a subfamily of atypical chemokine receptors (ACKRs) which are 50 generally stromally-expressed and which fine-tune in vivo chemokine activity by scavenging 51 chemokines and therefore regulating chemokine availability (13) (14) (15) . There are currently 4 members 52 of the atypical chemokine receptor family. ACKR1 (formerly known as DARC); ACKR2 (formerly known 53 as D6); ACKR3 (formerly known as CXCR7) and ACKR4 (formerly known as CCX-CKR). With the 54 exception of ACKR1, these receptors exhibit spontaneous internalisation and recycling activity and 55 scavenge chemokines from the environment and target them for lysosomal degradation. ACKR3 56 carries out this role in some essential developmental contexts and is strongly evolutionarily 57 conserved (5, 6, 16, 17) . ACKR4 scavenges chemokines within the lymph node to generate intra-lymph 58 node gradients and facilitate dendritic cell migration from the sub-capsular sinus into the T cell zone 59 of the lymph node(18). We have had a particular interest in ACKR2 which is the prototypic member of 60 the atypical chemokine receptor family(19). This receptor binds, internalises and degrades all 61 inflammatory chemokines belonging to the CC-chemokine subfamily and thus plays an essential role 62 in the resolution of the inflammatory response (20) (21) (22) (23) (24) . This has implications for tumorigenesis(25-28) 63 as well as for branching morphogenesis in a number of developmental contexts (29, 30) . ACKR2 is 64 predominantly expressed on lymphatic endothelial cells(31, 32) and placental trophoblasts (23, 33, 34) 65 with expression also being detected on subsets of splenic B cells(35). The atypical chemokine 66 receptors are therefore central regulators of chemokine activity in vivo. 67
One of the challenges in studying chemokine receptors, including atypical chemokine 68 receptors, is access to high quality antibodies. Whilst antibodies to some typical and atypical receptors 69 are available, it has proven extremely difficult to raise useful antibodies to others. For example, there 70 are no high-quality antibodies available for detection of murine ACKR2. A further issue is that even for 71 receptors for which antibodies are available, these antibodies are invariably species-specific and it is 72 therefore difficult to carry out analyses in either non-murine or non-human species. This is particularly 73 important for highly conserved receptors such as ACKR3. The availability of a generic methodology to 74 allow detection of atypical chemokine receptors (and amenable to detection of typical receptors), 75 which would be usable in vivo and applicable to numerous species, would therefore represent a 76 significant technological development. 77
Here we describe, a novel methodology for the detailed analysis of the phenotypes of ACKR2-78 expressing cells in lung stroma. The technology uses ACKR2-dependent internalisation of a 79 fluorescently tagged ligand to identify receptor expressing cells and we demonstrate the utility of 80 comparing intra-tracheal and intravenous administration in defining, and discriminating between, 81 discrete receptor expressing stromal cell types. We propose that this methodology will be broadly 82 applicable to a range of species and experimental analyses. 83 84
Materials and Methods 85
Mice 86 Animal experiments were performed using co-housed mice in ventilated cages in a barrier facility that 87 conformed to the animal care and welfare protocols approved by the University of Glasgow under the 88 revised Animal (Scientific Procedures) Act 1986 and the European Union Directive 2010/63/EU. Ackr2-89 deficient mice (Jamieson et al., 2005) were bred in-house (C57BL/6 background); wild type (WT) 90 C57BL6/J mice were from Charles River Research Models and Services. Prox-1 reporter mice were 91 obtained from Jackson laboratories. All experimental mice were sex and age matched. producing cDNA standards were designed using Primer3 software (http://frodo.wi.mit.edu/cgi-103 bin/primer3/primer3_www.cgi). The following primers were used: mouse ACKR2, 5'-104 TTCTCCCACTGCTGCTTCAC-3', 5'-TGCCATCTCAACATCACAGA-3'; mouse TBP primer: 5'-105 AAGGGAGAATCATGGACCAG-3', 5'-CCGTAAGGCATCATTGGACT-3'. 106 107
In-situ hybridisation 108
Mice were culled using increasing concentration of CO2. Lungs were placed in 10% neutral buffered 109 formalin at room temperature for 24-36 hours before they were processed by dehydration using rising 110 concentrations of ethanol, xylene stabilisation and paraffin embedding (Shandon citadel 1000, 111 Thermo Shandon). Tissue was then sectioned onto Superfrost plus slides (VWR) at 6μm using a 112 Microtome (Shandon Finesse 325 Microtome, Thermo). All slides for analysis were processed together. 113
Slides were baked at 60 o C for 1 hr before pre-treatment. Slides were deparaffinised with xylene (5 114 mins x 2) and dehydrated with ethanol (1 min x 2). In situ hybridisation was performed using the 115 RNAscope® 2.5 HD Reagent Kit-RED from Advanced Cell Diagnostics (cat. no. 322350) and according 116 to the manufacturer's instructions. Briefly tissues were incubated with Hydrogen peroxide for 10 mins 117 at RT. The slides were boiled in antigen retrieval buffer for 15 mins. Slides were treated with 'protease 118 plus' for 30 mins at 40 o C. Slides were then hybridised using the RNAScope 2.5 Red Manual Assay 119 (Advanced cell diagnostics) according to manufacturer's instructions using the Mm-ACKR2 probe 120 (NM_021609.4). Slides were mounted in DPX (Sigma Aldrich) and imaged on an EVOS M7000 121 microscope (Thermofisher). 122 123
Intratracheal and Intravenous Chemokine administration. 124
To administer fluorescent chemokine intratracheally mice were euthanised using an appropriate 125 schedule 1 method or CO2 exposure. The mice were then carefully dissected to remove the ribcage 126 and expose the intact lungs and trachea in situ. Using a pair of surgical scissors, a small incision was 127 made at the top of the exposed trachea toward the base of the jaw. A 2µg/ml solution of Alexa 647 TM 128 labelled CCL22 (Almac; Alexa-CCL22) dissolved in RPMI/25mM HEPES was prepared in a polypropolene 129 tube and preserved from light at room temperature until needed. Once the dissection was complete 130 a syringe with a 19G needle and loaded with 400µl of the Alexa-CCL22 solution was then inserted into 131 the exposed trachea via the incision. The needle should be tight within the trachea and care should 132 be taken not to pierce the trachea further down. The lungs were then inflated with the chemokine 133 solution and the trachea carefully tied off with surgical thread to prevent the leakage of chemokine 134 solution as the syringe is removed. The intact inflated lungs were then removed and placed into a 135 falcon tube containing enough RPMI to cover the intact inflated lungs. The lungs were then incubated 136 in a water bath for 1hour at 37 0 C. Following this time the lungs were removed from the waterbath 137 and the surgical thread cut to allow draining of the remaining chemokine solution. The lungs were 138 then digested for a single cell suspension as per the protocol. 139 140 Flow cytometry. 141
Lungs were removed and finely chopped with scissors, then incubated in digestion mix (1.6 mg/ml 142 Dispase (Roche),0.2 mg/ml Collagenase P (Roche) and 0.1mg/ml DNase I (Invitrogen)) in HBSS on a 143 gentle shake at 37 o C for 40 mins. Lungs were passed through a 40µm mesh (Greiner Bio-One), RBCs 144 were lysed in 1 ml RBC lysis buffer (eBioscience) for 1 min and then 10 mls Data on ACKR2 expression profiles available through the Immgen database (www.immgen.org) 181 reveal that the lung is the tissue with the highest expression (Supplemental Figure 1) . We have 182 previously described the versatile use of fluorescently labelled chemokines, instead of antibodies, to 183 detect their cognate receptors using flow cytometry as a read out (35) (36) (37) (38) . We used this approach with 184 Alexa-647 labelled CCL22 (a high affinity ACKR2 ligand: Alexa-CCL22) uptake to detect ACKR2 in lung 185 digests. Flow cytometric analysis of Alexa-CCL22 stained lung digests failed to detect any significant 186 expression on CD45+ leukocytes in either WT or ACKR2-/-lungs ( Figure 1a ). This therefore indicated 187 that ACKR2 expression in the lung was predominantly stromal in origin. We used RNA sequencing to 188 generate data on the transcriptional profile of FACS-sorted pulmonary stromal cell types at rest and 189 over the course of an influenza infection to examine possible pathogen-driven alterations in 190 expression. As shown in Figure 1b , ACKR2 expression was essentially undetectable in epithelial cells 191 but was present at low levels in fibroblasts and at very high levels in blood endothelial cells. Expression 192 did not vary significantly over the course of influenza infection. Examination of pulmonary ACKR2 193 expression by qPCR from embryonic day 13.5 to 9 weeks of age indicated that expression is low within 194 the embryo but that it is markedly upregulated immediately after birth and presumably coincident 195 with the onset of breathing. This increased level is maintained and increased as mice age (Figure 1c) . 196
Next, we tried to use the in vitro Alexa-CCL22 detection method to examine ACKR2 expression 197 on non-leukocytic stromal cells in the digested lung. However, and as shown in Figure 1d , this 198 technology, which works well with leukocytes (35, 38, 39) and mammary gland fibroblasts(30), 199 revealed only a minor difference in the numbers of Alexa-CCL22 internalising cells in WT or ACKR2-/-200 lungs. These data are summarised numerically in Figure 1e . 201
Overall, therefore, these data indicate that ACKR2 is predominantly expressed on stromal cells 202 within the lung but that flow cytometry utilising fluorescent chemokine uptake with digested lung 203 tissue has limited sensitivity to detect the key stromal expressing cell types. 204 205 Intra-tracheal fluorescent chemokine administration identifies key ACKR2-expressing stromal 206
components. 207
We reasoned that the function of stromal ACKR2 expression may be dependent on 208 interactions with other stromal components and that the inability to detect it using flow cytometry 209 reflects the inability to take up Alexa-CCL22 due to absence of these interactions. We therefore 210 harvested intact lungs, inflated them with Alexa-CCL22 (in RPMI) intra-tracheally followed by 211 incubation at 37°C for 1 hour (Figure 2a ). Following this, flow cytometric analysis of digested lungs 212 focusing on CD45-ve cellular populations now revealed a sizeable population of Alexa-CCL22 213 internalising cells in WT lungs which are absent from ACKR2-/-lungs ( Figure 2b ). These cells are non-214 epithelial as they are negative for EpCAM staining and these data are summarised numerically in 215 Figure 2c . Further flow cytometric analysis indicated that these cells fall into 3 basic categories as 216 defined by CD31 and Gp38 expression ( Figure 2d ). These represent fibroblasts (R1; CD31-Gp38-), 217 lymphatic endothelial cells (R2; CD31+Gp38+) and blood endothelial cells (R3; CD31+Gp38-) which are 218 enumerated as shown in Figure 2e . 219
Overall therefore these data demonstrate that it is possible to detect stromal cell populations 220 that bind and internalise Alexa-CCL22 via ACKR2 by introducing the chemokine intra-tracheally into 221 the intact lung. They also demonstrate novel stromal expression patterns for ACKR2 within the lung. 222
223

A subpopulation of Fibroblasts in the lung express ACKR2. 224
Cells identified in the R1 gate in Figure 2d , which were negative for markers of lymphatic and 225 vascular endothelial cells, were further phenotyped. Initially these cells were isolated by cell-sorting 226 and then grown in tissue culture. As shown in Figure 3a , the cells display a morphology suggestive of 227 a fibroblastic phenotype. Figure 3b further shows that the ACKR2+ fibroblastic cells were capable of 228 binding and internalising Alexa-CCL22 (arrow) confirming expression of functional ACKR2 (Figure 3b) . 229
Further flow cytometric analysis revealed that these cells are negative for markers of epithelial (CD166) 230 and endothelial (CD49f) cells but positive for the fibroblastic marker CD140a (Figure 3c ). Overall these 231 data indicate that one of the ACKR2-expressing stromal components in the lung detected by intra-232 tracheal Alexa-CCL22 administration is a fibroblastic subpopulation characterised by CD140a 233 expression. 234 235 Intravenous fluorescent chemokine administration identifies additional ACKR2-expressing stromal 236
components. 237
We have previously reported expression of ACKR2 in lymphatic endothelial cells(31), however 238 expression in blood endothelial cells as shown in Figures 2d and 2e has not been reported. In fact, and 239 as shown in Supplemental Figure 2 , comparison of transcriptomic data from a broad range of 240 microvascular endothelial types indicates that expression in blood endothelial cells is peculiar to the 241 lung. Given that we have reported polarisation of expression of ACKR2 in trophoblasts and lymphatic 242 endothelial cells (31, 34, 40) we wondered whether it may also be polarised in blood endothelial cells. 243
If this is the case then it is possible that the vascular facing aspect of endothelial cells may be more 244 able to internalise Alexa-CCL22 and thus the blood endothelial cell component might be 245 underestimated by the intra-tracheal administration of the chemokine. We therefore next injected 246 Alexa-CCL22 intravenously (Figure 4a ). Again, flow cytometric analysis revealed Alexa-CCL22 uptake 247 by 3 populations of non-epithelial stromal cells i.e. fibroblasts, blood endothelial cells and lymphatic 248 endothelial cells (Figure 4b ). However, and in contrast to intra-tracheal administration, intravenous 249 administration detected blood endothelial cells as being by far the dominant ACKR2-expressing 250 stromal population. Figure 4c shows that intravenous administration highlights blood endothelial cells 251 as being the predominant stromal cell component in the lung and comparing intra-tracheal 252 administration with intravenous administration (Figure 4d ) reveals the differences in cellular detection 253 using these two approaches. As we have previously shown expression of ACKR2 by lymphatic 254 endothelial cells(31, 32) it remained possible that what we have characterised as lung blood 255 endothelial cells are in fact lung lymphatic endothelial cells displaying an altered CD31/Gp38 256 phenotype compared to other lymphatic endothelial cell populations. To formally test this we 257 examined lung lymphatic endothelial cell expression of CD31 and Gp38 using Prox-1 reporter mice. 258
Prox-1 is a definitive marker and an essential master regulator, of lymphatic endothelial cells(41). As 259 shown in Figure 4e , Prox-1+ve cells from reporter mouse lungs were exclusively co-positive for CD31 260 and Gp38 confirming the faithfulness of the lymphatic phenotype in the lung. These data further 261 confirm the blood endothelial nature of the ACKR2+ve stromal cells. 262
In the lung there are two major blood vascular beds: one associated with bronchial tissues 263 and one with alveolar tissues. These can be discriminated on the basis of CD54 and CD31 264 expression(42). As shown in Figure 4f the Alexa-CCL22 internalising blood endothelial cell population 265 is strongly co-positive for CD31 and CD54 demonstrating that this population is associated with 266 alveolar blood vessels and not peribronchial blood vessels. 267 268
In situ hybridisation and antibody expression confirm blood endothelial cell expression of ACKR2 269
To further validate ACKR2 expression by murine pulmonary vascular endothelial cells, we 270 carried out in situ hybridisation. As shown in Figure 5a , clear in situ hybridisation signals were seen 271 associated with alveolar endothelial cells in blood vessels surrounding the alveolar air space in WT, 272 but not ACKR2-/-, adult murine lungs. A higher magnification image of a portion of Figure 5ai 
Discussion. 278
Atypical chemokine receptors are predominantly expressed on stromal cell types and serve 279 key functions in localising and fine-tuning chemokine activities (15) . Whilst a number of antibodies and 280 reporter mouse-based approaches are available for analysis of atypical chemokine receptor 281 expression patterns, in many cases these are limited and applicable only to mouse and humans. Given 282 that many of the atypical chemokine receptors display strong evolutionary conservation, other more 283 versatile approaches would therefore represent a significant improvement in the methodological 284 repertoire for atypical chemokine receptor expression analysis. Here we demonstrate, using the lung, 285 that fluorescently-labelled chemokines can be used, with intact tissues, to precisely isolate and 286 phenotypically define stromal cell types expressing individual atypical chemokine receptors. This is 287 particularly important when, as in the current analyses, removal of the cells from their stromal 288 environment impairs ACKR2 function and thus frustrates this detection methodology. The ability to 289 chemically synthesise chemokines with relative ease and to introduce discrete fluorescent markers at 290 the carboxy terminus(39) means that this approach has full versatility and is appropriate for all 291 members of the chemokine receptor family and all species expressing either typical or atypical 292 chemokine receptors. Importantly, whilst we demonstrate the utility of this approach using WT and 293 KO mice, the use of appropriate unlabelled competing chemokines specific for the receptor being 294 studied will allow this technology to be used under circumstances, or in species, where KO models do 295 not exist. 296
Here we show that intra-tracheal, and intra-venous, administration of fluorescently labelled 297 CCL22 is capable of identifying stromal cell populations expressing ACKR2. Importantly, in the context 298 of vascular endothelial cell expression, intravenous administration has the advantage of detecting 299 chemokine receptor expression with a polarity favouring expression on the luminal side of the 300 endothelium. Together these approaches allowed us to define fibroblasts, lymphatic endothelial cells, 301
and surprisingly alveolar blood endothelial cells as key sites of stromal ACKR2 expression in the lung. 302 Surprisingly, and in contrast to previous reports, we did not detect ACKR2 activity on alveolar 303 macrophages (43, 44) . This may be due to species differences in expression or alternatively may be a 304 consequence of non-specific antibody internalisation by the alveolar macrophages. Further analysis is 305 required to address this discrepancy. 306 Importantly this technology is applicable to other atypical chemokine receptors as well as to 307 the classical chemokine receptors and to any tissue which can be incubated in vitro with fluorescent 308 chemokines. This approach would, for example, be readily amenable for use with intestinal tissue, 309 liver and skin. 310
In summary therefore we report a methodology appropriate for detecting atypical chemokine 311 receptor expression in the lung which we believe to be sufficiently versatile to be useful to detect 312 other atypical and typical chemokine receptors in numerous tissues in vivo in divergent species. The 313 data indicate for the first time the stromal expression patterns of ACKR2 in the lung with notably high 314 expression levels on alveolar endothelial cells. These data will help interpret the outcome of analysis 315 of ACKR2 function the lung which remains poorly defined. 
